# Conexance MD

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/conexance-md

- Industry: Marketing/Advertising
- Headquarters: Lille, France
- Website: www.conexancemd.com
- Total disclosed funding: $3.5M
- Latest round: Series B (Sep 1, 2010)
- Investors on record: 3

## About

Conexance MD provides innovative medical technology solutions, specializing in advanced diagnostic tools and patient management systems designed to enhance healthcare delivery and streamline clinical processes.Conexance MD, founded in 2006 and headquartered in Lille, France, focuses on developing diagnostic and patient management technologies. The company has executed a total of 4 deals, with the most recent one on July 17, 2016. Conexance MD has received funding through a Series B round led by Turenne Groupe, raising EUR 1.801 mn, which is also the total amount raised to date, resulting in a current valuation of EUR 4.471 mn.Conexance MD specializes in providing innovative solutions within the medical technology sector, focusing primarily on advanced diagnostic tools and patient management systems. Their core product offerings are designed to enhance patient care and streamline clinical workflows, addressing common challenges faced by healthcare providers. These products cater to a diverse client base, including hospitals, diagnostic laboratories, and outpatient clinics, aiming to improve accuracy in diagnostics and bolster patient engagement. The company’s solutions have been deployed in various geographical markets, including North America and Europe, reflecting a commitment to addressing the needs of modern healthcare systems. Through their technology, Conexance MD strives to empower healthcare professionals by delivering tools that facilitate timely and informed decision-making.In the most recent year, 2022, Conexance MD reported revenue of EUR 6,873,471.80 and an EBITDA of EUR 1,444,669.80. The company generates revenue primarily through B2B transactions with healthcare institutions, establishing partnerships for their diagnostic and management solutions. Engagements typically involve service agreements, including subscription-based pricing or one-time licensing fees for flagship products. Clients may enter annual subscriptions that provide access to diagnostic platforms, ensuring continuous updates and support, which fosters long-term relationships and consistent revenue streams.Conexance MD is focusing on developing new products aimed at improving diagnostic capabilities and patient management. They are targeting expansions into new markets, specifically within Europe and potentially Asia, with plans to launch these initiatives by 2025. The recent Series B funding will support these developments, enabling the company to enhance their product offerings and grow their market presence. This growth follows the exit of XAnge Private Equity and Turenne Capital to WPP in July 2016, which generated a 2.4x multiple and an 18% IRR.

## Funding rounds

- Series B, Sep 1, 2010, $2.3M — Turenne Groupe, XAnge
- Series A, Aug 9, 2006, $1.1M — XAnge, Aurinvest Capital

## Investors

- XAnge (https://capitalatlas.ai/funds/xange) — Series A, Series B
- Aurinvest Capital (https://capitalatlas.ai/funds/aurinvest-capital) — Series A
- Turenne Groupe (https://capitalatlas.ai/funds/turenne-groupe) — Series B